Poison In Our Vaccines

By Lyn Redwood
Issue 115, November/December 2002

The author with her son, Will.More than 60 years ago, the Food and Drug Administration (FDA) approved a little-known product, thimerosal, to be used as a preservative. Today, many parents question if this product is responsible for the current epidemic of children diagnosed with learning disabilities and autism.

Thimerosal
Current thinking suggests that exposure to mercury comes primarily from environmental and dietary sources, dental amalgams, and rare catastrophic events. Recently, however, another common and pervasive source of mercury exposure has been identified. Called thimerosal, it was first approved as an additive by the FDA in the 1930s and has been utilized as a preservative to prevent bacterial contamination in a number of blood and biological products, including vaccines, immune globulins, and over-the-counter eye and nose drops.

The danger that thimerosal presents is that it contains 49.5 percent ethyl mercury by weight. Mercury is a potent human toxicant and has long been the source of many serious health problems. It is especially toxic to the rapidly developing fetal and infant brain. Federal agencies have published acceptable levels for exposure; but in actual fact mercury is a poison at any level. Chemically, thimerosal is a water-soluble, cream-colored crystalline powder. In the human body it is metabolized to ethyl mercury and thiosalicylate. The literature on thimerosal metabolism and excretion is old, and toxicological information is limited. In the past there have been case reports of toxicity and death following inadvertent massive exposures to thimerosal.

The FDA’s Discovery
The FDA Modernization Act, signed into law in 1997, included an amendment requiring the agency to compile a list of drugs and foods that contain intentionally introduced mercury compounds and to provide a quantitative and qualitative analysis of the mercury compounds on the list. One may ask why the FDA did not routinely perform this task. The FDA’s mission is to ensure purity, safety, potency, and efficacy of individual products, yet such analyses have never been a required part of the permitting process. In its review, which took two years to complete, the FDA discovered that infants who receive vaccines containing thimerosal may be exposed to more mercury than recommended by federal guidelines for total mercury exposure.

Infant vaccines that routinely contained thimerosal were DPT (diphtheria-pertussis-tetanus), hepatitis B, and Hib (Hemophilus influenzae type b). Following the vaccination schedule recommended by the Centers for Disease Control (CDC), infants were exposed to anywhere from 0.0 to 187.5 mcg of ethyl mercury, depending on the vaccine manufacturer, and total exposure over 18 months could be as high as 237.5 mcg. The dose the Environmental Protection Agency (EPA) deems allowable is 0.1 mcg per kilogram per day. If an average 5 kg-infant received all thimerosal-containing vaccines at his two-month visit, his exposure that day would be 62.5 mcg ethyl mercury–125 times as great as the EPA guideline.

In its analysis, the FDA multiplied EPA’s daily exposure levels of 0.1 mcg per kilogram by 180 days, even though the exposures had occurred on only four days during this time period. It is perplexing that the FDA chose to average an infant’s total exposure to mercury over the first six months of life as though children were being exposed on a daily basis, and reported that amounts were only slightly above one of the federal guidelines. According to toxicologists, because of the inherent pharmokinetics of mercury and its long half-life in the body, the effect of a large injected dose cannot be calculated as though it were ingested in small amounts over a longer period of time. This method of analysis inaccurately minimizes the levels of exposure. If one were to look at the mercury in thimerosal from a daily dose perspective, no one vaccine containing thimerosal would meet EPA’s guidelines for safe exposure. A simple analogy can be made that since one may safely consume four Tylenol a day in six-hour intervals for a month, consuming 120 Tylenol in one day would be equally safe. (In fact, it would be a fatal dose.) At the same time the FDA findings were released, the American Academy of Pediatrics (AAP) published an interim report to physicians on thimerosal in vaccines. In the report, the AAP and Public Health Service agreed that the use of thimerosal-containing vaccines should be reduced or eliminated, stating that any potential risk was of concern.1 While this report discussed much of the uncertainty regarding the potential effect of mercury exposure in vaccines, it clearly stated that there was no evidence of harm having occurred from such exposure. The report also said, “Infants and children who have received thimerosal-containing vaccines do not need to have blood, urine, or hair tested for mercury since the concentrations would be quite low and would not require treatment.” Without such tests, of course, it was impossible to know for a fact that there was no “evidence of harm.”

Historical Perspective
It is interesting to note that thimerosal was introduced only a few years before Leo Kanner, MD, described a new mental disorder that differed “markedly and uniquely from anything reported” before.2 In its early history autism was diagnosed more frequently in affluent families, but by the 1970s it had become more evenly distributed socioeconomically. This apparent widening in demographics paralleled the increasing availability of vaccines to all children through federally sponsored programs.

The 1980s and especially the 1990s saw a tremendous increase in the occurrence of autism spectrum disorders (ASD). In the late 1980s and early 1990s, the vaccine schedule was amended to include both hepatitis B and Hib vaccines, each administered to infants three times during the first six months of life. Their addition to the vaccine schedule potentially tripled an infant’s exposure to mercury, should he receive all thimerosal-containing vaccines. An additional concern is that these vaccine exposures occur on top of prenatal exposures from immune globulin preparations (administered during pregnancy to Rh- mothers) and from dietary, dental, and environmental exposures.

Current Investigations
Recent information from large epidemiological studies conducted in mercury-exposed populations suggests that intermittent large exposures may pose more risk than daily small exposures. One study investigated children who had suffered prenatal exposure to intermittent bolus doses of methyl mercury (found in fish) via the mothers’ diets. The exposure level was thought to be safe at the time. However, when evaluated years later, the children were found to have lower scores on memory, attention, language, and motor function tests.3

In a recent investigation, mercury levels were obtained before and after exposure to 12.5 mcg of ethyl mercury in hepatitis B vaccine in 15 preterm and 5 term infants.4 There were no differences between the two groups with respect to mean prevaccination levels, although postvaccination mercury levels were significantly increased in both groups of infants. Postvaccination levels in preterm infants were three times higher than those of term infants, a difference that was statistically significant. One preterm infant developed a postvaccinal mercury level of 23.6 mcg per liter, which falls within the range known to result in neurodevelopmental dysfunction.5

At the June 21, 2000, meeting of the Advisory Committee for Immunization Practices, held in Atlanta, Thomas Verstraeten of the National Immunization Program presented a review of vaccine safety datalink information on thimerosal-containing vaccines.6 Over 400,000 children participate in the vaccine safety datalink program. From this database, 100,000 charts were reviewed to determine exposure to thimerosal-containing vaccines and specific neurodevelopmental outcomes. Statistically significant associations were found between cumulative exposure to thimerosal-containing vaccines at two months of age and unspecified developmental delay; three months of age and tics; six months of age and attention deficit disorder; one, three, and six months of age and speech and language delay and neurodevelopmental delays in general. According to a report in the Weekly Epidemiology Record that reviewed the use of thimerosal as a vaccine preservative, “This safety assessment cannot currently exclude the possibility of subtle neurodevelopmental abnormalities in infants from a cumulative exposure to thimerosal in vaccines.”7

What Next?
Among the many unknowns about thimerosal are a paucity of data on the metabolism, excretion, and toxicity of ethyl mercury; the levels of risk to the fetus from maternal exposures and to the infant from exposure occurring during critical windows of neurological development; and the effect of large intermittent bolus exposures to ethyl mercury compared to daily low-dose oral exposures to methyl mercury. These concerns are being addressed in investigations by governmental and private agencies.

There appears to be no general consensus as to how best to diagnose and treat elevated mercury levels in children. The effectiveness of chelating agents in crossing the blood-brain barrier has become a topic of scrutiny, along with the possibility of treating a long-standing exposure that occurred during a critical time in development. At a recent conference, a number of physicians who specialize in the treatment of autism and developmental disorders reported finding many children with elevated mercury levels who had remarkable improvement in behaviors, speech, and cognition when treated with a program to reduce oxidative stress and metal body burden.8

What To Do
Despite this information, the FDA has only “encouraged” vaccine manufacturers to reduce or eliminate thimerosal. Until there is more research assuring its safe use in infants, it would only be prudent to give preference to all thimerosal-free vaccines. Writing about thimerosal, Neal Halsey of the Johns Hopkins University Institute for Vaccine Safety stated, “We can say there is no evidence of harm, but the truth is no one has looked.”9

Numerous vaccine products containing thimerosal are still on the market. Both the general public and health care providers need to be aware of the availability of vaccine products with and without thimerosal. Parents research the safest car seats and toys for their children but do not realize that they need to research vaccines as well. Thimerosal has been eliminated from latex paints, Merthiolate, and many other products because of its serious toxic effects on infants. Although the FDA has only focused on thimerosal in infant vaccines at this time, all vaccines that contain this product should come under scrutiny in the near future.

NOTES
1. American Academy of Pediatrics, “Thimerosal in Vaccines: An Interim Report to Clinicians,” www.aap.org/new/thimpublic.htm, accessed October 18, 1999.
2. L. Kanner, “Autistic Disturbances of Affective Contact,” The Nervous Child 2, no. 3 (1942-1943): 217-250.
3. P. Grandjean et al., “Cognitive Performance of Children Prenatally Exposed to ‘Safe’ Levels of Methylmercury,” Environ. Res. 77 (1998): 165-172.
4. G. Stajich et al., “Iatrogenic Exposure to Mercury after Hepatitis B Vaccination in Preterm Infants,” J. Pediatrics 136, no. 5 (2000): 679-681.
5. P. Grandjean, et al., “Methylmercury: Significance of Intrauterine and Postnatal Exposures,” Clin. Chem. 40, no. 7 (1994): 1395-1400.
6. P. Stehr-Green, “Review of Vaccine Safety Datalink Information on Thimerosal-Containing Vaccines,” presentation to the Advisory Committee on Immunization Practices, June 7-8, 2000.
7. “Thimerosal as a Vaccine Preservative,” Wkly. Epi. Rec. 75, no. 2 (2000): 12-16.
8. Defeat Autism Now conference, Boston, Spring 2002.
9. “Uproar Over a Little-Known Preservative, Thimerosal, Jostles US Hepatitis B Vaccination Policy,” Hep. Control Rep. 4, no. 2 (Summer 1999).

FOR MORE INFORMATION

Books

Cave, Stephanie, MD. What Your Doctor May Not Tell You About Children’s Vaccinations. Warner Books, 2001.

Hamilton, Lynn M. Facing Autism: Giving Parents Reasons for Hope and Guidance for Help. Waterbrook Press, 2000.

McCandless, Jaquelyn, MD. Children with Starving Brains: A Medical Treatment Guide for Autism Spectrum Disorder. Bramble Company, 2002.

Maurice, Catherine. Let Me Hear Your Voice: A Family’s Triumph Over Autism. Fawcett Books, 1994.

Paradi, Valerie. Elijah’s Cup: A Family’s Journey into the Community and Culture of High-Functioning Autism and Asperger’s Syndrome. Free Press, 2002.

Seroussi, Karyn. Unraveling the Mystery of Autism and Pervasive Developmental Disorder: A Mother’s Story of Research & Recovery. Simon & Schuster, 2000.

Waites, Junee and Helen Swinbourne. Smiling at Shadows: A Mother’s Journey Raising an Autistic Child. Ulysses Press, 2002.

Websites

www.autismresearchinstitute.com

www.autism-mercury.com

www.canfoundation.org

www.safeminds.org

www.909shot.com

For additional information on autism, see the following articles in past issues of Mothering: “Show Us the Science,” no. 105 and “Promising Approaches,” no. 100.

Lyn Redwood RN, MSN, CRNP, is a writer, researcher, and president of SAFEMINDs (Sensible Action For Ending Mercury Induced Neurological Disorders). She has three children, Hanna, Drew, and Will.

For more information on vaccines see the Mothering Reprint: Vaccines: Mercury, Autism and Chronic Disease